These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 34507895)

  • 1. The safety and efficacy evaluation of sodium-glucose co-transporter 2 inhibitors for patients with non-alcoholic fatty liver disease: An updated meta-analysis.
    Mo M; Huang Z; Liang Y; Liao Y; Xia N
    Dig Liver Dis; 2022 Apr; 54(4):461-468. PubMed ID: 34507895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of sodium-glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
    Xing B; Zhao Y; Dong B; Zhou Y; Lv W; Zhao W
    J Diabetes Investig; 2020 Sep; 11(5):1238-1247. PubMed ID: 32083798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium-Glucose Cotransporter-2 Inhibitors Ameliorate Liver Enzyme Abnormalities in Korean Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.
    Euh W; Lim S; Kim JW
    Front Endocrinol (Lausanne); 2021; 12():613389. PubMed ID: 34177796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists versus thiazolidinediones for non-alcoholic fatty liver disease: A network meta-analysis.
    Ding C; Tang Y; Zhu W; Huang P; Lian P; Ran J; Huang X
    Acta Diabetol; 2022 Apr; 59(4):519-533. PubMed ID: 34988690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium-glucose cotransporter inhibitors as add-on therapy in addition to insulin for type 1 diabetes mellitus: A meta-analysis of randomized controlled trials.
    Zou H; Liu L; Guo J; Wang H; Liu S; Xing Y; Deng C; Xiao Y; Zhou Z
    J Diabetes Investig; 2021 Apr; 12(4):546-556. PubMed ID: 33245620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolution of liver fibrosis in diabetic patients with NAFLD in a follow-up study: Hepatoprotective effects of sodium-glucose co-transporter-2 inhibitors.
    Lombardi R; Mantovani A; Cespiati A; Francione P; Maffi G; Del Zanna E; Maffeis C; Colecchia A; Passigato N; Ferrarese A; Cusumanu CD; Villani R; Orsi E; Grancini V; Airaghi L; Bignamini D; Serviddio G; Targher G; Dongiovanni P; Fargion S; Fracanzani AL
    Dig Liver Dis; 2024 Apr; 56(4):551-558. PubMed ID: 37845152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of sodium glucose cotransporter 2 inhibitors on hepatic fibrosis and steatosis in non-alcoholic fatty liver disease: an updated systematic review and meta-analysis.
    Ong Lopez AMC; Pajimna JAT
    Sci Rep; 2024 Jan; 14(1):2122. PubMed ID: 38267513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Long-term Efficacy of Sodium Glucose Co-transporter 2 Inhibitor in Patients with Non-alcoholic Fatty Liver Disease.
    Yamashima M; Miyaaki H; Miuma S; Shibata H; Sasaki R; Haraguchi M; Fukushima M; Nakao K
    Intern Med; 2019; 58(14):1987-1992. PubMed ID: 31308341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of semaglutide in non-alcoholic fatty liver disease.
    Zhu K; Kakkar R; Chahal D; Yoshida EM; Hussaini T
    World J Gastroenterol; 2023 Oct; 29(37):5327-5338. PubMed ID: 37899788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of intermittent fasting regimens on glycemic, hepatic, anthropometric, and clinical markers in patients with non-alcoholic fatty liver disease: Systematic review and meta-analysis of randomized controlled trials.
    Saleh SAK; Santos HO; Găman MA; Cerqueira HS; Zaher EA; Alromaih WR; Arafat NS; Adi AR; Adly HM; Alyoubi R; Alyahyawi N; Kord-Varkaneh H
    Clin Nutr ESPEN; 2024 Feb; 59():70-80. PubMed ID: 38220409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Sodium Glucose Co-Transporter 2 Inhibitors on Liver Fat Mass and Body Composition in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus.
    Arase Y; Shiraishi K; Anzai K; Sato H; Teramura E; Tsuruya K; Hirose S; Deguchi R; Toyoda M; Mine T; Kagawa T
    Clin Drug Investig; 2019 Jul; 39(7):631-641. PubMed ID: 30993553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of aldafermin in non-alcoholic steatohepatitis: A systematic review and meta-analysis of randomized controlled trials.
    Marey MM; Belal M; Awad AA; Rabea EM; Hassan MA; Abbas AW; Nashwan AJ
    Clin Res Hepatol Gastroenterol; 2024 Jun; 48(6):102357. PubMed ID: 38688423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcomes in lean and non-lean NAFLD patients: a systematic review and meta-analysis.
    Huang S; Bao Y; Zhang N; Niu R; Tian L
    Endocrine; 2024 Jul; 85(1):134-141. PubMed ID: 37253855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review.
    Raj H; Durgia H; Palui R; Kamalanathan S; Selvarajan S; Kar SS; Sahoo J
    World J Diabetes; 2019 Feb; 10(2):114-132. PubMed ID: 30788048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mendelian randomisation reveals Sodium-glucose Cotransporter-1 inhibition's potential in reducing Non-Alcoholic Fatty Liver Disease risk.
    Dobbie LJ; Cuthbertson DJ; Hydes TJ; Alam U; Zhao SS
    Eur J Endocrinol; 2023 Jun; 188(6):K33-K37. PubMed ID: 37343141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative effects of sodium-glucose cotransporter-2 inhibitors on liver functions in patients with nonalcoholic fatty liver disease.
    Chen X; Xu C; Hu K; Yang Y; Zhang YJ; Shi HZ; Gu Q; He SM; Zhang C; Wang DD
    Expert Rev Clin Pharmacol; 2023; 16(10):991-998. PubMed ID: 37669251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of chicory supplementation on liver enzymes and lipid profiles in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of clinical evidence.
    Maleki E; Sadeghpour A; Taherifard E; Izadi B; Pasalar M; Akbari M
    Clin Nutr ESPEN; 2023 Jun; 55():447-454. PubMed ID: 37202083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis of the clinical efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease.
    Xu YY; Wang X; She YQ; Liu J; Zhang Q
    Endocr J; 2024 Sep; 71(9):881-894. PubMed ID: 38910131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The therapeutic effect of continuous blood purification on sepsis in children: A systematic review and meta-analysis.
    Zhang M; Ling Z; Zhang W; Huang Q
    J Infect Chemother; 2024 Jul; ():. PubMed ID: 39033814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of sodium-glucose cotransporter-2 inhibitors and thiazolidinediones for management of non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Hameed I; Hayat J; Marsia S; Samad SA; Khan R; Siddiqui OM; Khan MO; Malik S; Fatima K; Fudim M; Krasuski RA
    Clin Res Hepatol Gastroenterol; 2023 May; 47(5):102111. PubMed ID: 36931466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.